Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pneumolysin (Ply) mutant and application thereof as mucosal immunoadjuvant

A technology for Streptococcus pneumoniae and mutants, which is applied in the field of medicine and biology, can solve the problems of high toxicity and cannot be applied to the human body, and achieves the effect of facilitating separation and purification

Active Publication Date: 2014-07-23
CHONGQING MEDICAL UNIVERSITY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a classic mucosal adjuvant, CT (cholera toxin) adjuvant has a remarkable effect, but it cannot be used in humans due to its high toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pneumolysin (Ply) mutant and application thereof as mucosal immunoadjuvant
  • Pneumolysin (Ply) mutant and application thereof as mucosal immunoadjuvant
  • Pneumolysin (Ply) mutant and application thereof as mucosal immunoadjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Construction of recombinant expression plasmids pET28a(+)-ΔPly, pET28a(+)-DnaJ, pET28a(+)-DnaJ-ΔPly and pET28a(+)-ΔPly-DnaJ expression vectors

[0033] (1) Materials:

[0034] Plasmid pET28a(+) was purchased from Novagen, Prime Star high-fidelity enzyme, dNTPs, Buffer, MgCl for PCR 2 Purchased from Dalian Bao Biological Technology Co., Ltd., PTC-200 PCR instrument is a product of Perkin Elmer, and RG-3000 is a product of Corbett Research.

[0035] (2) Design and synthesis of primers:

[0036] Using Streptococcus pneumoniae TIGR4 genomic DNA as a template, referring to its complete sequence (GeneBank number AE005672), primers were designed using Premier 5.0 and synthesized by Shanghai Sangong Company.

[0037] Construction reference of pET28a(+)-ΔPly recombinant plasmid (Lea-Ann S.Kirkham, Infect.Immun.2006,74(1):586.), construction reference of pET28a(+)-DnaJ recombinant plasmid (Mohd.Nadeem Khan , Vaccine 24 (2006) 6225–6231.)

[0038] DnaJ: upstream primer: 5'-GGA...

Embodiment 2

[0117] Expression, Identification and Purification of Prokaryotic Expression Plasmids pET28a(+)-ΔPly, pET28a(+)-DnaJ, pET28a(+)-DnaJ-ΔPly and pET28a(+)-ΔPly-DnaJ in Escherichia coli

[0118] (1) Transformation of recombinant plasmids pET28a(+)-ΔPly, pET28a(+)-DnaJ, pET28a(+)-DnaJ-ΔPly and pET28a(+)-ΔPly-DnaJ into the host strain BL21(DE3)

[0119] (2) IPTG induces the massive expression of ΔPly, DnaJ, DnaJ-ΔPly and ΔPly-DnaJ

[0120] (3) Purification of the recombinant protein: After the bacteria were broken by ultrasound, the supernatant of the broken bacteria was taken for purification; 4°C, 10000rpm×10min, the supernatant was filtered with a 0.45μm membrane filter, and the filtrate was collected for later use.

[0121] Affinity chromatography purification: aspirate 2ml of 50% Ni 2+ -NTA resin suspension in the chromatography column, equilibrate with 20ml sonication buffer; suck out the equilibrated Ni 2+ -NTA resin suspension and the above filtrate are fully mixed, ice-ba...

Embodiment 3

[0135] Evaluation of the effect of ΔPly as an adjuvant for mucosal immunity

[0136] (1) C57 mice were randomly divided into 6 groups, including single protein immunization group (1 group in total, DnaJ group), pairwise mixed immunization group (2 groups in total, DnaJ+ΔPly group and DnaJ+GST group respectively) ) and fusion protein immunization groups (group 2, DnaJ-ΔPly group and ΔPly-DnaJ group) and the positive control group of CT adjuvant (group 1, group CT+DnaJ).

[0137] (2) For the first immunization, use sterile PBS to adjust the recombinant protein concentration and immunize the mice in the experimental group by nasal drop, each 30ul, containing 8ugDnaJ and / or 10ugΔPly recombinant protein, 18ug of fusion protein, and 1ug of CT adjuvant;

[0138] (3) One week after the first immunization, the second immunization was carried out, the method and dose were the same as above, and the CT adjuvant was halved.

[0139] (4) Two weeks after the first immunization, the third i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pneumolysin (Ply) mutant and an application thereof as a mucosal immunoadjuvant. A gene of the mutant comprises deltaPly with nucleotide sequence of SEQ ID NO.2. The Ply mutant (deltaPly) is used as the mucosal immunoadjuvant to prepare streptococcus pneumoniae fusion protein vaccines to prevent streptococcus pneumoniae infection immunity and is safe and effective.

Description

technical field [0001] The invention relates to the field of medical biotechnology, in particular to a pneumolysin mutant and its application as a mucosal immune adjuvant. Background technique [0002] Pneumonia is currently the leading cause of death in children, surpassing HIV / AIDS, malaria and measles. According to the available etiological investigation results, Streptococcus pneumoniae is the main bacteria causing fatal pneumonia infection in children. The existing vaccines against Streptococcus pneumoniae on the market are mainly 23-valent polysaccharide vaccines and polysaccharide conjugate vaccines (7-valent, 11-valent, 13-valent, etc.) against Streptococcus pneumoniae, but they all exist: limited coverage of serotypes, possible Capsular serotype conversion and other disadvantages, and because the conjugate vaccine is relatively expensive, it is difficult to incorporate into national immunization in developing countries. Therefore, developing a new pneumococcal pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/315C07K19/00C12N15/62C12N15/70A61K39/39A61K39/09A61P31/04
CPCA61K39/00C07K14/3156C07K2319/00C12N15/62
Inventor 尹一兵张雪梅刘宇思胥文春王虹
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com